SPP2 Antibody

What is SPP2 and why is it significant in biomedical research?

SPP2 (Secreted Phosphoprotein 2), also known as SPP24, is a secreted phosphoprotein with a length of 211 amino acid residues and a molecular weight of approximately 24.3 kDa in humans. It is primarily expressed in the liver and secreted into plasma, playing roles in skeletal system development and various biological processes. SPP2 has been identified as a secreted factor that negatively regulates liver regeneration, inhibits cysteine protease activity, participates in bone formation, inhibits calcification, and regulates the BMP/TGF-β signaling pathway . Recent research has established SPP2 as a potential tumor suppressor that inhibits the development of hepatocellular carcinoma (HCC) by inhibiting the BMP/TGF-β signaling pathway . The protein's expression is significantly related to many genes, including APOA1, SLC2A2, and TTR, and its expression level is up-regulated in liver cirrhosis .

What applications are SPP2 antibodies commonly used for?

SPP2 antibodies are employed in numerous experimental applications across biomedical research. The most common applications include:

These applications allow researchers to investigate SPP2 expression, localization, and interactions in various experimental contexts .

What species reactivity is available for SPP2 antibodies?

SPP2 antibodies are available with reactivity against several species, which is important for comparative and translational research. The most common reactivities include:

When selecting an antibody, researchers should verify cross-reactivity with their species of interest and validate the antibody in their specific experimental system .

How does SPP2 influence the BMP/TGF-β signaling pathway and what antibody-based techniques can best detect this interaction?

SPP2 has been identified as an antagonist of BMP signaling both in vitro and in vivo . For researchers investigating this interaction, several antibody-based approaches can be used:

• Co-immunoprecipitation (Co-IP) using SPP2 antibodies can help identify protein-protein interactions between SPP2 and components of the BMP/TGF-β pathway.

• Proximity ligation assays (PLA) can detect close associations between SPP2 and BMP receptors or downstream effectors using specific antibodies against each protein.

• Chromatin immunoprecipitation (ChIP) assays using antibodies against SMAD proteins (downstream of BMP signaling) can help determine how SPP2 affects transcriptional responses.

• Immunofluorescence co-localization studies can visualize spatial relationships between SPP2 and BMP pathway components.

Research has shown that SPP2 deficient mice demonstrate altered BMP signaling responses, suggesting SPP2 may regulate this pathway by binding to BMP ligands or receptors, thereby preventing normal signal transduction . When designing experiments to investigate this interaction, researchers should consider both canonical and non-canonical BMP signaling pathways and employ phospho-specific antibodies to detect activation states of pathway components.

What are the technical considerations for using SPP2 antibodies in liver regeneration studies?

When investigating SPP2's role in liver regeneration, several important technical considerations should be addressed:

• Temporal dynamics: SPP2 expression changes during regeneration phases, so researchers should collect samples at multiple time points after injury (6, 24, 48, and 72 hours post-injury are commonly used time points).

• Regional heterogeneity: Immunohistochemistry with SPP2 antibodies should examine zonal differences in expression across the liver lobule, as periportal and pericentral hepatocytes may show differential regulation.

• Cell-type specificity: Use dual immunofluorescence with cell-type markers (hepatocytes, stellate cells, Kupffer cells) alongside SPP2 antibodies to determine which cells express and respond to SPP2.

• Injury model selection: Different models (acetaminophen, carbon tetrachloride, partial hepatectomy) may show varying SPP2 expression patterns and functions .

• Background strain considerations: When using genetic models (such as Spp2 knockout mice), background strain can influence regenerative capacity and should be controlled for.

Research has demonstrated that Spp2 deficient mice show increased survival after acetaminophen poisoning and reduced fibrosis after repeated carbon tetrachloride injections, highlighting SPP2's role as a negative regulator of liver regeneration . Properly optimized antibody-based detection methods are essential for accurately characterizing this role in different experimental contexts.

How can SPP2 antibodies be used to investigate its potential tumor suppressor function in hepatocellular carcinoma?

To investigate SPP2's potential tumor suppressor function in hepatocellular carcinoma (HCC), researchers can employ several antibody-based approaches:

• Expression profiling: Immunohistochemistry using SPP2 antibodies can compare expression levels between normal liver, cirrhotic tissue, and HCC samples at various stages. This can establish correlations between SPP2 expression and disease progression .

• Prognostic significance: Tissue microarray analysis with SPP2 antibodies can determine if expression levels correlate with patient outcomes, potentially identifying SPP2 as a prognostic biomarker.

• Mechanistic studies: Co-immunoprecipitation with SPP2 antibodies followed by mass spectrometry can identify novel protein interactions in HCC cells versus normal hepatocytes.

• Functional genomics: After CRISPR-mediated knockout or overexpression of SPP2, antibodies can verify expression changes and detect alterations in downstream signaling pathways, particularly BMP/TGF-β components.

• Therapeutic response: SPP2 antibodies can monitor expression changes following treatment with various therapeutic agents to determine if SPP2 modulation correlates with treatment efficacy.

Recent studies suggest that SPP2 may inhibit HCC development by suppressing the BMP/TGF-β signaling pathway . Researchers should consider both autocrine and paracrine effects of SPP2, as it is primarily produced by the liver but may act on various cell types within the tumor microenvironment.

What are the optimal protein extraction methods when preparing samples for SPP2 antibody detection via Western blot?

When preparing samples for SPP2 antibody detection via Western blot, researchers should consider the protein's secreted nature and potential post-translational modifications:

• For cellular samples:

  • Use a lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, supplemented with protease inhibitors.

  • Include phosphatase inhibitors (sodium orthovanadate, sodium fluoride) to preserve phosphorylation states.

  • Perform lysis on ice for 30 minutes with periodic vortexing.

  • Centrifuge at 14,000 × g for 15 minutes at 4°C to remove cellular debris.

• For secreted SPP2 in conditioned media:

  • Collect serum-free conditioned media after 4-5 days in culture.

  • Remove cell debris by centrifugation at 3,000 × g for 10 minutes.

  • Concentrate the media using Amicon Ultra Centrifugal Filter Units or similar concentration devices .

  • Consider TCA precipitation for very dilute samples.

• For tissue samples:

  • Liver tissue, which highly expresses SPP2, should be homogenized in RIPA buffer with protease inhibitors.

  • Include a mechanical disruption step (using a bead beater or homogenizer) for complete lysis.

  • Filter homogenates through a 100 μm cell strainer to remove connective tissue.

When running Western blots, load 20-50 μg of total protein for cellular/tissue lysates or concentrated conditioned media equivalent to 1-2 ml of original volume. Use human placenta tissue as a positive control, as it has demonstrated reactivity in previous studies . For optimal detection, use antibody dilutions between 1:1000-1:6000 as recommended by manufacturers .

How should researchers troubleshoot non-specific binding or weak signals when using SPP2 antibodies?

When encountering non-specific binding or weak signals with SPP2 antibodies, researchers should systematically address several potential issues:

• For non-specific binding:

  • Increase blocking time and concentration (5% BSA or milk in TBST for 2 hours).

  • Optimize primary antibody dilution by performing a dilution series (1:500 to 1:6000).

  • Increase washing stringency (use 0.1% Tween-20 in TBS, wash 5 times for 5 minutes each).

  • Consider using a different blocking agent (switch between BSA and milk).

  • Pre-absorb the antibody with recombinant protein if specific peptide is available.

  • Validate antibody specificity with positive and negative controls (such as SPP2 knockout samples or siRNA-treated cells).

• For weak signals:

  • Increase protein loading amount (up to 80-100 μg for total lysates).

  • Reduce antibody dilution within the recommended range (1:1000 instead of 1:6000) .

  • Extend primary antibody incubation time (overnight at 4°C).

  • Use enhanced chemiluminescence substrates with higher sensitivity.

  • For secreted SPP2, further concentrate conditioned media samples.

  • Consider using a signal enhancer solution before primary antibody incubation.

  • Check sample preparation method to ensure protein integrity is maintained.

• Application-specific troubleshooting:

  • For IHC/IF: Optimize antigen retrieval methods (try citrate buffer pH 6.0 or EDTA buffer pH 9.0).

  • For IP: Increase antibody amount or bead volume to improve capture efficiency.

  • For ELISA: Adjust coating buffer pH to optimize antibody binding to the plate.

If problems persist, consider using alternative antibody clones or formats. Always verify reactivity with your specific sample type, as SPP2 antibodies have been validated for various applications including WB, IF, IHC, and ELISA with specific reactivity against human and rat SPP2 .

What considerations should be made when selecting between different SPP2 antibody conjugates for specific applications?

Selecting the appropriate SPP2 antibody conjugate requires careful consideration of the experimental goals and detection system:

When selecting a conjugate, researchers should consider:

• Sensitivity requirements: If detecting low abundance SPP2, unconjugated or biotin-conjugated antibodies with signal amplification steps may be preferable.

• Multiplexing needs: For co-localization studies with multiple proteins, directly conjugated fluorescent antibodies in spectrally distinct channels are advantageous.

• Background concerns: In tissues with high endogenous biotin (like liver, which highly expresses SPP2), avoid biotin-conjugated antibodies or use blocking steps.

• Detection system compatibility: Ensure the conjugate is compatible with available imaging or detection equipment.

• Species cross-reactivity: Verify that the conjugated antibody maintains reactivity with the species of interest, as conjugation can sometimes affect binding properties .

For SPP2 detection in liver samples, which highly express the protein, unconjugated antibodies may provide the most flexibility in optimization. For multiple labeling experiments, directly conjugated fluorophores like AbBy Fluor 647 or Cy7 can be valuable, as demonstrated in previous studies .

How should researchers design controls for SPP2 antibody validation experiments?

Proper antibody validation is critical for ensuring experimental reproducibility and data reliability. For SPP2 antibody validation, researchers should implement the following controls:

• Positive controls:

  • Human placenta tissue for Western blot (confirmed positive in previous studies)

  • Liver tissue sections (primary site of SPP2 expression) for IHC/IF

  • Recombinant SPP2 protein at known concentrations for quantitative applications

  • Cell lines with confirmed SPP2 expression (such as hepatocyte cell lines)

• Negative controls:

  • SPP2 knockout or knockdown samples (CRISPR-Cas9 or siRNA treated)

  • Tissues or cell types known not to express SPP2

  • Isotype control antibodies matched to the SPP2 antibody host species and class

  • Secondary antibody-only controls to assess background

• Specificity controls:

  • Peptide blocking experiments using the immunogen peptide or recombinant SPP2

  • Detection of SPP2 at the expected molecular weight (24 kDa) in Western blot

  • Comparison of staining patterns across multiple antibodies targeting different SPP2 epitopes

  • Correlation of protein detection with mRNA expression

• Application-specific controls:

  • For secreted SPP2: Compare concentrated conditioned media from cells with and without SPP2 expression

  • For proximity biotinylation assays: Use non-SPP2 fusion proteins with the same tag as controls

  • For post-translational modification studies: Include dephosphorylation treatment controls

A comprehensive validation approach should verify that the antibody detects SPP2 with the expected molecular weight (24 kDa), tissue distribution (primarily liver), and cellular localization (secreted protein) . Whenever possible, researchers should correlate antibody-based detection with orthogonal methods such as mass spectrometry or mRNA quantification.

What are the best practices for quantifying SPP2 expression levels in different experimental contexts?

Accurate quantification of SPP2 expression requires careful consideration of the protein's biology and appropriate technical approaches:

• For Western blot quantification:

  • Use housekeeping proteins appropriate for the sample type (β-actin for cellular lysates, albumin for serum samples)

  • For secreted SPP2, normalize to total protein concentration in conditioned media

  • Use standard curves with recombinant SPP2 for absolute quantification

  • Employ densitometry software (ImageJ, Image Lab) with background subtraction

  • Ensure signal is within the linear range of detection

• For immunohistochemical quantification:

  • Use digital image analysis software with consistent thresholding

  • Quantify both staining intensity and percentage of positive cells

  • Generate H-scores or similar semi-quantitative measures

  • Compare against standardized positive controls in each batch

  • Account for regional heterogeneity in liver samples by analyzing multiple fields

• For ELISA-based quantification:

  • Develop standard curves using recombinant SPP2 protein

  • Ensure samples fall within the linear range of the assay

  • Run technical triplicates for statistical validity

  • Include inter-assay calibrators for multi-plate experiments

  • Consider matrix effects, especially for serum/plasma samples

• For flow cytometry quantification:

  • Use median fluorescence intensity rather than mean

  • Include fluorescence minus one (FMO) controls

  • Convert to antibody binding capacity using calibration beads

  • Gate populations consistently across samples

When comparing SPP2 expression across experimental conditions (such as normal versus cirrhotic liver or different stages of liver regeneration), ensure consistent protocol execution including sample collection, processing, storage, and analysis methods . For secreted SPP2, standardize the time of conditioned media collection (typically 4-5 days) and concentration methods .

How can researchers effectively use SPP2 antibodies in proximity biotinylation assays to identify interaction partners?

Proximity biotinylation assays represent a powerful approach to identify potential interaction partners of SPP2. Based on previous research methodologies , researchers can effectively implement these techniques with the following protocol:

• Construct preparation:

  • Generate an SPP2-APEX2 fusion protein expression construct

  • Include a control construct with APEX2 alone or a non-relevant protein fused to APEX2

  • Verify construct expression and secretion via Western blot using SPP2 antibodies

• Experimental setup:

  • Transfect HEK293T cells with SPP2-APEX2 construct

  • Collect conditioned media after 2-3 days

  • Apply the conditioned media containing SPP2-APEX2 to target cells (e.g., hepatocytes)

  • Incubate for 90 minutes to allow potential interactions to form

  • Wash with PBS thoroughly

• Biotinylation procedure:

  • Incubate cells with 500μM biotin-phenol in complete medium for 30 minutes

  • Trigger biotinylation by adding 1mM H₂O₂ for 1 minute

  • Quench reaction immediately with appropriate quenching buffer

  • Lyse cells and collect biotinylated proteins using streptavidin beads

• Controls and validation:

  • Include cells without SPP2-APEX2 treatment as negative controls

  • Use SPP2-Flag conditioned medium as an additional control

  • Perform Western blotting with SPP2 antibodies to confirm SPP2-APEX2 presence

  • Validate potential interactions with co-immunoprecipitation using SPP2 antibodies

• Mass spectrometry analysis:

  • Process samples for mass spectrometry

  • Consider proteins with fold change greater than 2 as potential interactors

  • Validate top hits with orthogonal methods

This approach has successfully identified integrin family members as interaction partners of SPP2, which partly explain its role in regeneration phenotypes . When analyzing results, consider the cellular localization of identified proteins and their biological relevance to SPP2's known functions in BMP signaling, liver regeneration, or bone formation.

What emerging applications of SPP2 antibodies show promise for future research?

SPP2 antibodies are poised to play pivotal roles in several emerging research areas:

• Liquid biopsy development: As SPP2 is a secreted protein whose expression changes in liver disease states, antibody-based detection in serum could enable development of non-invasive diagnostic tests for liver fibrosis, regeneration capacity, or HCC risk assessment .

• Therapeutic target validation: SPP2 antibodies will be crucial for validating the efficacy of therapeutic strategies aimed at modulating SPP2 function, particularly in contexts of impaired liver regeneration or excessive fibrosis .

• Single-cell protein analysis: Integration of SPP2 antibodies into mass cytometry (CyTOF) or other single-cell protein analysis platforms could reveal cell-specific expression patterns and signaling responses across heterogeneous liver cell populations.

• Spatial proteomics: Combining SPP2 immunodetection with spatial transcriptomics or multiplexed antibody imaging could map the protein's distribution in relation to its signaling partners across tissue microenvironments.

• Drug discovery platforms: Antibody-based screening assays to identify compounds that modulate SPP2's interactions with BMP/TGF-β pathway components or integrin receptors could yield therapeutic candidates for liver diseases .

The recent identification of SPP2 as a negative regulator of liver regeneration through CRISPR screening highlights the value of combining genetic approaches with antibody-based detection methods . Future research will likely expand on these findings to develop more comprehensive models of SPP2's roles in health and disease, with antibodies serving as critical tools in this endeavor.

How can researchers integrate SPP2 antibody-based detection with other -omics approaches for comprehensive functional studies?

Integrating SPP2 antibody-based detection with other -omics approaches can provide comprehensive insights into this protein's functions:

• Antibody-based proteomics integration:

  • Combine immunoprecipitation using SPP2 antibodies with mass spectrometry (IP-MS) to identify interaction partners

  • Use reverse phase protein arrays (RPPA) with SPP2 antibodies to quantify expression across large sample cohorts

  • Employ antibody-based proximity extension assays to measure SPP2 in biobank samples alongside other proteins

• Transcriptomics integration:

  • Correlate SPP2 protein levels (detected by antibodies) with mRNA expression in single-cell or spatial transcriptomics data

  • Perform SPP2 knockdown or overexpression followed by RNA-seq to identify regulated genes

  • Compare transcriptomic changes in Spp2 deficient mice with protein-level alterations detected by antibodies

• Functional genomics integration:

  • Use SPP2 antibodies to validate in vivo CRISPR screening hits related to liver regeneration

  • Combine ChIP-seq using antibodies against transcription factors with SPP2 protein expression data

  • Validate genetic variants associated with SPP2 expression through antibody-based quantification

• Metabolomics integration:

  • Correlate SPP2 levels detected by antibodies with metabolic profiles in normal and diseased states

  • Investigate how SPP2's effects on BMP signaling impact metabolic pathways using combined antibody detection and metabolite analysis